NASDAQ:GLYC

GlycoMimetics - GLYC Stock Forecast, Price & News

$3.09

+0.06 (+1.98%)

(As of 02/3/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.97
▼
$3.12
50-Day Range: $2.04
▼
$3.39
52-Week Range: $0.51
▼
$3.60

Volume: 380,625 shs
Average Volume: 986,260 shs
Market Capitalization: $161.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

GlycoMimetics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$2.85 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.91) to ($0.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

608th out of 1,028 stocks

Pharmaceutical Preparations Industry

294th out of 501 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for GlycoMimetics.

3.0

Short Interest

Percentage of Shares Shorted
1.56% of the float of GlycoMimetics has been sold short.
Short Interest Ratio / Days to Cover
GlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GlycoMimetics has recently increased by 7.78%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
GlycoMimetics does not currently pay a dividend.
Dividend Growth
GlycoMimetics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for GlycoMimetics is -0.55.

2.2

News and Social Media Coverage

News Sentiment
GlycoMimetics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for GlycoMimetics this week, compared to 1 article on an average week.
Search Interest
15 people have searched for GLYC on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.
MarketBeat Follows
10 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GlycoMimetics insiders have sold 628.61% more of their company's stock than they have bought. Specifically, they have bought $390,500.00 in company stock and sold $2,845,225.00 in company stock.
Percentage Held by Insiders
Only 8.00% of the stock of GlycoMimetics is held by insiders.
Percentage Held by Institutions
49.50% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for GlycoMimetics are expected to grow in the coming year, from ($0.91) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GlycoMimetics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GlycoMimetics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GlycoMimetics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

January 30, 2023 | americanbankingnews.com

Insider Selling: GlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Sells $2,125,572.16 in Stock

January 22, 2023 | finance.yahoo.com

GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To Profit

February 5, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now!

January 22, 2023 | finance.yahoo.com

This Small Pharma Company Could Develop Into a Nice Trade

December 26, 2022 | finance.yahoo.com

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Invest In Growth?

December 12, 2022 | finance.yahoo.com

GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

December 3, 2022 | americanbankingnews.com

GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com

December 2, 2022 | finance.yahoo.com

Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?

February 5, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

December 2, 2022 | finance.yahoo.com

Individual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18%

November 23, 2022 | finance.yahoo.com

After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright

November 12, 2022 | finance.yahoo.com

GlycoMimetics Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)

November 10, 2022 | finance.yahoo.com

Insiders at GlycoMimetics, Inc. (NASDAQ:GLYC) recouped some losses this week after buying this year, still down US$49k

November 9, 2022 | finance.yahoo.com

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022

November 8, 2022 | finance.yahoo.com

GlycoMimetics to Participate in Two Upcoming Investor Conferences

November 3, 2022 | finance.yahoo.com

GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting

November 2, 2022 | finance.yahoo.com

GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022

October 19, 2022 | globenewswire.com

Acute Myeloid Leukemia Market Size to Surpass US$ 4.31 Billion by 2030 - Growth Plus Reports - GlobeNewswire

October 19, 2022 | benzinga.com

Venous Thromboembolism Pipeline Assessment – Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Drug - Benzinga

October 13, 2022 | businesswire.com

Vaso-occlusive Crisis-associated with Sickle Cell Disease Drug Pipeline Report 2022 - ResearchAndMarkets.com - Business Wire

October 11, 2022 | businesswire.com

BIO Announces Appointment of Interim CEO - Business Wire

October 4, 2022 | finance.yahoo.com

GlycoMimetics (GLYC) Upgraded to Buy: Here's Why

September 21, 2022 | benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session - bluebird bio (NASDAQ:BLUE), Apexigen (NASDAQ - Benzinga

September 16, 2022 | benzinga.com

Sickle Cell Disease Treatment Global Market to Reach $4 Billion by 2027 - Benzinga

September 14, 2022 | streetinsider.com

Form 425 Maxpro Capital Acquisiti Filed by: Apollomics Inc. - StreetInsider.com

September 9, 2022 | benzinga.com

Sickle Cell Disease Treatment Global Market Report 2022: Increase in the Number of Individuals Suffering - Benzinga

September 8, 2022 | nasdaq.com

GlycoMimetics Says Edwin Rock Joins As Chief Medical Officer - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Company Calendar

Last Earnings: 11/09/2022
Today: 2/04/2023
Next Earnings (Estimated): 3/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLYC
CUSIP: N/A
CIK: 1253689
Web: www.glycomimetics.com
Phone: (240) 243-1201
Fax: 301-738-2137
Employees: 52
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,430,000.00
Net Margins: N/A
Pretax Margin: -57,921.50%
Return on Equity: -85.00%
Return on Assets: -72.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.95
Quick Ratio: 6.95

Sales & Book Value

Annual Sales: $92,625.00
Price / Sales: 1,748.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.58 per share
Price / Book: 1.96

Miscellaneous

Outstanding Shares: 52,424,000
Free Float: 48,230,000
Market Cap: $161.99 million
Optionable: Optionable
Beta: 2.08

Key Executives

Harout Semerjian
President, Chief Executive Officer & Director

Brian M. Hahn
Chief Financial Officer & Senior VP-Finance

John L. Magnani
Chief Scientific Officer & Senior VP-Research

Deepak Tiwari
Vice President-Technical Operations

Edwin P. Rock
Chief Medical Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings or view top-rated stocks.
How have GLYC shares performed in 2023?: GlycoMimetics' stock was trading at $3.03 at the beginning of 2023. Since then, GLYC stock has increased by 2.0% and is now trading at $3.09.
View the best growth stocks for 2023 here.
When is GlycoMimetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GLYC earnings forecast.
How were GlycoMimetics' earnings last quarter?: GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.10.

What other stocks do shareholders of GlycoMimetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX).
What is GlycoMimetics' stock symbol?: GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
Who are GlycoMimetics' major shareholders?: GlycoMimetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Intellectus Partners LLC (0.16%), AE Wealth Management LLC (0.05%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews and Scott D Sandell.
View institutional ownership trends.
How do I buy shares of GlycoMimetics?: Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GlycoMimetics' stock price today?: One share of GLYC stock can currently be purchased for approximately $3.09.
How much money does GlycoMimetics make?: GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $161.99 million and generates $92,625.00 in revenue each year. The biotechnology company earns $-63,430,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.
How can I contact GlycoMimetics?: GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 2/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GlycoMimetics - GLYC Stock Forecast, Price & News

GlycoMimetics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About GlycoMimetics (NASDAQ:GLYC) Stock

GLYC Stock News Headlines

GLYC Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GLYC Stock - Frequently Asked Questions

Overall MarketRank^™